|1.||De Clercq, E: 2 articles (12/2000 - 03/2000)|
|2.||Balzarini, J: 1 article (12/2000)|
|3.||Degrève, B: 1 article (12/2000)|
|4.||Esnouf, R: 1 article (12/2000)|
|5.||Andrei, G: 1 article (03/2000)|
|6.||Sandvold, M L: 1 article (03/2000)|
|7.||Myhren, F: 1 article (03/2000)|
|8.||Snoeck, R: 1 article (03/2000)|
|9.||Neyts, J: 1 article (03/2000)|
03/01/1998 - "The longer retention time of the GCV metabolites most likely explains why E-GCV is superior to GCV against herpes simplex virus replication and HSVtk gene-transfected tumor cell proliferation. "
03/01/1998 - "The cytostatic activity of E-GCV to the HSVtk gene-transfected tumor cells was far superior to that of GCV. "
03/01/1998 - "Taking into account the marked stability of E-GCV in human plasma and its much higher lipophilicity than GCV, E-GCV should be considered as an effective lipophilic prodrug of GCV with a markedly enhanced cytostatic activity in HSVtk gene-transfected tumor cells compared with parental ganciclovir. "
03/01/1998 - "E-GCV was at least 2000-fold more cytostatic to HSV-1 or HSV-2 thymidine kinase (tk) gene-transfected mammary carcinoma FM3A tk-/HSVtk+ tumor cells than to the corresponding nontransfected tumor cells. "
03/01/1998 - "Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells."
|3.||Osteosarcoma (Osteogenic Sarcoma)
03/01/2000 - "A fatty acid derivative of ganciclovir (GCV), elaidic acid ganciclovir (E-GCV), has been evaluated for its inhibitory activity against laboratory and clinical strains of herpes simplex type 1 (HSV-1) and type 2 (HSV-2), varicella-zoster virus (VZV) and human cytomegalovirus (HCMV) in human embryonic lung fibroblasts. "